NOT-MH-25-025: Notice of Early Expiration of PAR-23-165 " Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01 Clinical Trial Not Allowed)"

Notice of Early Expiration of PAR-23-165 " Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01 Clinical Trial Not Allowed)"

Notice Number:

NOT-MH-25-025

Key Dates

Release Date:

October 10, 2024

Related Announcements

April 7, 2023 - "Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorder (R01 Clinical Trial Not Allowed)"- See NOFO PAR-23-165.

Issued by

National Institute of Mental Health (NIMH)

Purpose

This Notice informs applicants of the early expiration of PAR-23-165 "Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01 Clinical Trial Not Allowed)". The last receipt date for this NOFO will be January 7, 2025. NIMH encourages applicants interested in developing novel human PET or SPECT radioligands to apply to PAR-23-164 “Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01 Clinical Trial Optional)”.

Currently Reads:

Key Dates have been modified as follows:

Current Expiration:

May 8, 2026

New Expiration:

January 8, 2025

All other aspects of this NOFO remain the same.

Inquiries

Please direct all inquiries to:

Enrique Michelotti, Ph.D.
National Institute of Mental Health (NIMH)
Telephone: 301-443-5415
Email: [email protected]